Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM

News Conference News HFSA 2025

Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM

Yael L. Maxwell

October 01, 2025

HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM

News Conference News ESC Heart Failure 2025

HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM

May 19, 2025

Even on Tafamidis, ATTR-CM Patients Face High Mortality Over Time

News Daily News

Even on Tafamidis, ATTR-CM Patients Face High Mortality Over Time

Michael O'Riordan

February 13, 2025

Acoramidis Approved in Europe for ATTR Cardiomyopathy

News Daily News

Acoramidis Approved in Europe for ATTR Cardiomyopathy

Michael O'Riordan

February 12, 2025

Before a Cardiomyopathy Diagnosis, TTR Destabilization Portends Higher Mortality

News Daily News

Before a Cardiomyopathy Diagnosis, TTR Destabilization Portends Higher Mortality

Yael L. Maxwell

December 12, 2024

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

News Daily News

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

November 25, 2024

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

News Conference News HFSA 2024

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

October 04, 2024

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

News Conference News ESC 2024

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

August 30, 2024

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

News Daily News

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Michael O'Riordan

June 24, 2024

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

News Conference News ESC 2023

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

Michael O'Riordan

August 31, 2023

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

News Daily News

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

October 20, 2021

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

News Features

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

December 23, 2019

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

News Daily News

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Michael O'Riordan

May 06, 2019

Tafamidis, a Transthyretin Stabilizer, Offers Hope for Rare Cardiomyopathy

News Conference News ESC 2018

Tafamidis, a Transthyretin Stabilizer, Offers Hope for Rare Cardiomyopathy

Michael O'Riordan

August 27, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.